Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc reported multiple equity awards and related exercises for its Chief Medical Officer, John F. Paolini, on April 1, 2026. He received a share option for 26,750 Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036, that vests over time starting April 1, 2026.
He was also granted 6,700 Restricted Share Units and 13,400 Performance Share Units, each linked to Class A Ordinary Shares and subject to four-year time-based or performance-based vesting, with PSUs eligible to convert into up to 200% of one share each by January 30, 2029. In addition, Paolini exercised previously granted RSUs for 5,831 Class A Ordinary Shares, with 2,821 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Paolini directly holds 64,334 Class A Ordinary Shares, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported multiple equity awards and related share activity. On April 1, 2026, he received a share option grant for 36,950 shares with an exercise price of $48.13 per share, expiring on March 31, 2036.
He was also granted 9,250 Restricted Share Units and 18,500 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year vesting and, for PSUs, performance criteria through January 30, 2029. On the same date, he exercised previously granted RSUs into 5,808 Class A Ordinary Shares, with 1,706 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Moat held 14,396 Class A Ordinary Shares directly. Earlier, on January 15, 2026, he acquired 879 Class A Ordinary Shares at $24.16 per share under the company’s 2018 Employee Share Purchase Plan, an acquisition noted as exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported multiple equity compensation transactions. On April 1, 2026, he received a share option for 14,600 shares at an exercise price of $48.13, vesting over four years starting April 1, 2026.
He was also granted 3,650 Restricted Share Units and 7,300 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year time- and performance-based vesting. The filing shows RSU exercises converting into 7,564 Class A Ordinary Shares, with 3,205 shares withheld at $48.13 to cover tax obligations.
Following these transactions, Megna directly holds 31,777 Class A Ordinary Shares. Footnotes describe prior participation in the 2018 Employee Share Purchase Plan and detail vesting schedules for the options, RSUs, and PSUs, including potential PSU settlement by January 30, 2029 based on performance.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Kiniksa Pharmaceuticals International Plc common stock, representing 0% of the class. The filing states an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report separately. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction. On March 9, 2026, he exercised options covering 36,722 Class A Ordinary Shares at exercise prices between $17.76 and $26.74 per share. The same day, he sold 17,981 shares at $45.58 per share and 18,741 shares at $46.24 per share in open‑market transactions. These sales, totaling 36,722 shares, were carried out under a pre‑arranged Rule 10b5‑1 trading plan executed on August 14, 2025. Following the transactions, Ragosa directly owned 12,086 Class A Ordinary Shares.
Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026. The filing lists 36,722 shares in the securities-to-be-sold row and discloses prior sales by Mark Ragosa of 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, with corresponding proceeds of $502,628.00 and $772,311.00.
FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock. The filing shows FMR LLC (and Abigail P. Johnson in related capacity) beneficially owns 4,854,354.23 shares, equal to 10.6% of the class as reported with a 02/27/2026 reference. The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. The schedule includes an Exhibit 99 13d-1(k)(1) agreement and signatures by an authorized representative on 03/05/2026.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares. He exercised a fully vested option for 40,000 Share Options at an exercise price of $10.36 per share, acquiring 40,000 Class A Ordinary Shares on March 2, 2026. That same day, he sold a total of 40,000 Class A Ordinary Shares in open-market transactions at weighted average prices ranging from about $43.555 to $46.09, under a Rule 10b5-1 plan executed on November 18, 2025. After these transactions, he directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options.
Kiniksa Pharmaceuticals, Ltd. submitted a Rule 144 notice reporting the sale of 40,000 Class A ordinary shares on 03/02/2026. The transaction is described as an employee stock option exercise settled as a broker payment for a cashless exercise through Charles Schwab & Co., Inc..
Kiniksa Pharmaceuticals International, plc reports its annual business overview, highlighting a commercial rare-disease franchise and a focused cardiovascular pipeline. The company markets ARCALYST, an IL‑1α/IL‑1β cytokine trap, as the first and only FDA‑approved therapy for recurrent pericarditis, targeting an estimated 40,000 treated patients in the United States.
Kiniksa is advancing KPL‑387, an IL‑1 receptor monoclonal antibody with FDA Orphan Drug Designation for pericarditis, through a Phase 2/3 recurrent pericarditis program, with Phase 2 data expected in the second half of 2026. Preclinical KPL‑1161 aims for quarterly dosing, while development of abiprubart in Sjögren’s Disease has been discontinued as the company explores strategic options for the asset.
The business model combines internal development with partnerships. Kiniksa evenly splits ARCALYST profits and certain proceeds with Regeneron, has out‑licensed vixarelimab to Genentech with potential milestones and royalties, and granted Huadong rights to ARCALYST in a broad Asia‑Pacific territory. Intellectual property protection extends across composition, methods of use and formulations, supplemented by U.S. and EU regulatory exclusivities.